💰 $1B+ Class Actions — Advisory Approval

Friday, May 15, 2026 · Internal review only · Voice: litigation-grade (settlement-economics overlay)
Today's Briefing Lead

Mega-deal payout cycle is unusually dense. BCBS Subscriber ($2.67B) began distribution to ~7.8M claimants on May 11 (JND administering). Bartz v. Anthropic ($1.5B) fairness hearing held May 14 — under submission; 91.3% claims rate is a class-action high-water mark. Purdue ($7.4B) effective May 1; first tranche of Sackler payments now in trust. Visa/Mastercard "revised" interchange (~$38B value) heads toward late-2026 final approval. Bayer Roundup ($7.25B class) fairness July 9, 2026. Defense bar already framing the Duane Morris $79B 2025 top-10 aggregate as inflated by forward-looking valuation methodology. Watch: Bartz final approval order; first Roundup objection wave; ISS SCAS Q2 Top-100 refresh.

Today's Advisory (collapsible)
Open full advisory
▼

Active mega-deal payouts

BCBS Subscriber Antitrust ($2.67B). JND Legal Administration began payments May 11, 2026 to approximately 7.8 million approved claimants in In re Blue Cross Blue Shield Antitrust Litigation (MDL 2406, N.D. Ala., Judge R. David Proctor). Net distributable ~$1.9B after fees and admin costs. Tiered pro rata: claims <$5 receive no first-round payment; $5–$200 paid in full; ≥$200 receive 90% in round one with 10% held in reserve for true-up. Methods: check, PayPal, Venmo, electronic debit card.

Bartz v. Anthropic ($1.5B). Largest copyright settlement in U.S. history. Fairness hearing held yesterday (May 14, 2026) before Judge Araceli Martínez-Olguín — under submission. 91.3% claims rate (440,490 of 500,000 covered works). Per-work compensation ~$3,000. Unsealed objections target: exclusion of foreign/non-U.S.-registered works; publisher-over-author allocation; class-notice adequacy; quantum relative to damages; class-counsel conflict of interest. Cross-link Tab 02 (LLM/Copyright).

Purdue/Sackler ($7.4B). Re-confirmed plan effective May 1, 2026 (per Mich. AG implementation order). Initial tranche: ~$1.5B Sacklers + ~$900M Purdue. Subsequent Sackler tranches: $500M May 2027, $500M May 2028, $400M May 2029. New non-profit Knoa Pharma receives Purdue's assets. April 29 NJ federal criminal sentencing cleared dissolution path. ProPublica and victim advocates continue to flag documentation/exclusion gaps. Cross-link Tab 07.

Pending — preliminary approval & fairness

Visa/Mastercard "revised" interchange (~$38B value). Announced Nov 10, 2025 in In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation (MDL 1720, E.D.N.Y., Judge Margo Brodie). Successor to the 2024 deal Judge Brodie rejected. Headline terms: 10 bps interchange cut for five years; 1.25% rate cap on standard consumer credit for eight years (premium rewards excluded); HAC rule relaxation; surcharge/decline flexibility for merchants. Final approval expected late 2026 / early 2027. NRF, NACS, NRA, Walmart, and Hugo Boss have all objected.

Bayer Roundup class ($7.25B / 21 years). Rule 23(b)(3) NHL claimants. Preliminary approval March 2026; fairness hearing July 9, 2026 (N.D. Cal.). Per-claimant ceiling ~$165K (exposure × disease grade × age). Bayer aggregate Roundup spend now ~$11B; Q3 2025 provisions €11.8B (€9.6B glyphosate-specific). Objector commentary targeting the lawyer-fee-to-class-recovery ratio.

Industry-data snapshot

Cornerstone Research 2025 review. 74 securities class-action settlements totaling $3.0B; median settlement amount near three-decade high at $17.3M. ISS SCAS 2025: 115 court-approved monetary settlements (down 15% YoY); 8 mega-settlements ($100M+) totaling $1.6B+. New top-100 entries: Alibaba ($433.5M), GE ($362.5M). 2025 disbursements include Kraft Heinz $450M (May) and Alphabet $350M (July). 2026 pipeline: Didi Global $740M, Rivian $250M, Celgene $239M, FIS $210M.

Duane Morris 2026 Class Action Review. Top-10 class-action settlements aggregated to $79B in 2025 (up from $42B in 2024 — third consecutive year above $40B). 13,000+ federal class actions filed in 2025 (~36/day). 68% of class-certification motions granted (up from 63%). Generative AI and crypto added as standalone categories for the first time. Defense commentary frames the figure as inflated by deal-valuation methodology (Visa/Mastercard interchange relief valued on projected forgone fees over many years).

Cross-references & watchlist (next 60 days)

Bartz final approval order is the gating event of the week (cross-link Tab 02). BCBS Subscriber distribution pace (second-distribution timing). Roundup class fairness July 9, 2026. Visa/Mastercard objection briefing schedule. J&J talc tort track post-bankruptcy-exit (cross-link Tab 07). Disney v. Midjourney class-cert briefing. OpenAI/Microsoft S.D.N.Y. consolidated track scheduling. Tesla securities lead-plaintiff motions. ISS SCAS Q2 Top-100 refresh.

Voice grade: litigation-grade (settlement-economics overlay). Audience: see project dir background.md.
Key Dates (next 60 days)
Bartz v. Anthropic final approval order (post-May 14 fairness hearing) — N.D. Cal., Judge Martínez-Olguín. Cross-link Tab 02.
BCBS Subscriber second-distribution timing — JND administration; 10% holdback on ≥$200 claims.
Bayer Roundup class fairness — July 9, 2026, N.D. Cal. Objector turnout on lawyer-fee ratio.
Bayer Q2 2026 earnings — early August. Roundup accrual changes.
Duane Morris / CFO Dive mid-year update — typically early July. 2026-YTD aggregate.
ISS SCAS Top-100 quarterly refresh — Didi Global $740M, Celgene $239M additions.
9th Cir. / D.C. Cir. uninjured-class-members cert watch — Olean / Rail Freight / Asacol split.
Disney v. Midjourney class-cert briefing — image-training corollary to Bartz.
Tesla securities lead-plaintiff motions & consolidation order — N.D. Cal. (likely).
LinkedIn Post (proposed)
Today's mega-class action calibration — three deals are moving simultaneously and the structural story isn't the dollars, it's the claims rates. • BCBS Subscriber ($2.67B antitrust): JND began distributing on May 11 to ~7.8M claimants. Net distributable ~$1.9B after fees/admin. Pro rata with $5 floor + 10% holdback on ≥$200. The mechanics are textbook — it's the second-distribution timing that will define the cycle. • Bartz v. Anthropic ($1.5B copyright): Fairness hearing held yesterday before Judge Martínez-Olguín. 91.3% claims rate (440,490 of 500,000 works). For context: consumer mega-classes routinely settle below 5%. Bartz is now the high-water benchmark for Rule 23(e)(2)(C)(ii) fairness — and the implicit floor for any pirated-corpus settlement going forward. • Purdue/Sackler ($7.4B): Plan effective May 1. Initial $1.5B Sacklers + $900M Purdue at effectiveness. Knoa Pharma takes the operating assets. Subsequent tranches scheduled through 2029. Duane Morris pegs the 2025 top-10 aggregate at $79B (third consecutive year above $40B). Defense bar already pushing back that the figure is inflated by forward-looking deal-valuation methodology — particularly the Visa/Mastercard interchange relief valued on projected forgone fees. Watch the fee-multiplier ruling and the foreign-works objection on Bartz. Watch the lawyer-fee-to-class-recovery ratio in the Roundup fairness brief (hearing July 9). The objectors are getting better organized. #ClassAction #Settlement #Antitrust #MegaSettlement #Securities
✓ Copied
Not legal advice. Voice grade: litigation-grade (settlement-economics overlay). Verify all docket and agency citations against primary sources before acting. Knowledge baseline at references/background.md.